| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Apr 01, 2021 |
Director, President and CEO
Trans History: 27
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 775,000 | -- | 775,000 |
| Apr 01, 2021 |
Chief Operating Officer
Trans History: 16
|
Chief Operating Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 275,000 | -- | 275,000 |
| Apr 01, 2021 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 275,000 | -- | 275,000 |
| Jan 22, 2021 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 8,000 | $6.00 | 8,000 |
| Sep 03, 2020 |
Chief Medical Officer
Trans History: 9
|
Chief Medical Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Sep 03, 2020 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
| Sep 01, 2020 |
Chief Medical Officer
Trans History: 9
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- | 300,000 |
| Sep 01, 2020 |
Chief Medical Officer
Trans History: 9
|
Chief Medical Officer | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- | 300,000 |
| Sep 01, 2020 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 350,000 | -- | 350,000 |
| Sep 01, 2020 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 225,000 | -- | 225,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.